CDH2 and prostate carcinoma: Here, data from prostate cancer indicate that peptides and mouse monoclonal antibodies targeting N-cadherin proved some efficacy in inhibiting prostate cancer metastasis and enhancing cancer cell sensitivity to chemotherapeutic agents [24].